ABEMA Study: For patients with ER+ HER2- Early Breast Cancer

Therapy on Trial: Giredestrant and Abemaciclib

Study Information

Study Title

An Open-Label, Single Arm Substudy to Explore the Safety and Efficacy of Giredestrant in Combination with Abemaciclib in Patients with Estrogen-Receptor Positive, HER2 Negative Early Breast Cancer (lidERA Substudy)

Study Summary

The purpose of this clinical trial is to evaluate the safety of giredestrant in combination with abemaciclib for participants with high-risk node-positive ER+ HER2− EBC who have completed (neo)adjuvant chemotherapy and have had surgery.

Disease State

ER+, HER2- Breast Cancer

Principal Investigator

Myron Bednar, MD

Phase III

If you have any questions regarding this study or think that you or your loved one may be eligible, please contact our Clinical Trial Coordinator by dialing 908.237.1201 extension 262.

Contact HHO

All questions and feedback are welcome, anytime.

    About HHO

    Hunterdon Hematology Oncology is a community oncology group, dedicated to fighting cancer in this community and across the region. Our Doctors, Physician’s Assistants and Nurses work tirelessly. They fight hard so that you can win.


    Sign up for the HHO newsletter to stay up to date on the latest news within the practice and the community.

      © HHO 2022. All rights reserved. Designed by DRAW